NCT05657834

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

A Phase I, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-TVB-2640 Following a Single Oral Dose in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Sagimet Biosciences Inc. · Industry
• Sex: Male
• Age: 19 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]TVB-2640 healthy male subjects.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	[14C]-TVB-2640	50 mg of TVB-2640 oral administration

Timeline

• Start date: 2022-11-21
• Primary completion: 2022-12-21
• Completion: 2022-12-21
• First posted: 2022-12-20
• Last updated: 2022-12-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study